论文部分内容阅读
自70年代普遍开展联合化疗以来,成人急性白血病(AL)预后有显著改观。但目前化疗药物及剂量的选择大多根据AL患者群体一般反应性而缺少个体化。临床疗效监测是了解白血病细胞化疗敏感性的方法之一。本文以白血病祖细胞(LCFU)和粒系-巨噬系祖细胞(GM-CFU-c)两种体外培养技术检测了37例急性非淋巴细胞白血病(ANLL)患者,旨在正确评价个体因素对化疗疗效的影响。找出提高缓解率的途径。研究对象和方法病例 37例ANLL患者GM-GFU-c体外培养67例次,其中28例52例次同时进行L-CFU体外培养。患者平均年龄33.7(14～
The prognosis for adult acute leukemia (AL) has improved significantly since the widespread chemotherapy in the 1970s. However, the current choice of chemotherapy drugs and dosage is mostly based on the general reactivity of AL patients and lack of individualization. Clinical efficacy monitoring is one of the ways to understand the chemosensitivity of leukemia cells. In this study, 37 acute leukemia patients with acute lymphoblastic leukemia (ANLL) were tested in vitro by leukemia progenitor cells (LCFU) and GM-CFU-c in order to evaluate the effect of individual factors Effect of chemotherapy. Find ways to improve remission rates. PARTICIPANTS AND METHODS Cases A total of 67 cases of GM-GFU-c were cultured in 37 ANLL patients in vitro. Twenty-eight of the 52 cases were simultaneously cultured with L-CFU in vitro. The average age of patients was 33.7 (14 ~